NASDAQ:CEMI

Chembio Diagnostics - CEMI Stock Forecast, Price & News

$0.36

-0.01 (-1.48%)

(As of 09/26/2022 01:08 PM ET)

Add

Compare

Today's Range: $0.36
▼
$0.37
50-Day Range: $0.35
▼
$1.10
52-Week Range: $0.34
▼
$2.74

Volume: 1,323 shs
Average Volume: 706,928 shs
Market Capitalization: $10.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Chembio Diagnostics (NASDAQ:CEMI) Stock

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Stock News Headlines

September 20, 2022 | americanbankingnews.com

Chembio Diagnostics (NASDAQ:CEMI) Coverage Initiated by Analysts at StockNews.com

September 6, 2022 | finance.yahoo.com

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

September 3, 2022 | finance.yahoo.com

Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed

August 16, 2022 | finance.yahoo.com

Rapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It Off

August 16, 2022 | finance.yahoo.com

Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development

August 4, 2022 | finance.yahoo.com

Chembio Diagnostics Reports Second Quarter 2022 Financial Results

July 21, 2022 | finance.yahoo.com

Chembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022

June 15, 2022 | baystreet.ca

Chembio Expands Distribution

June 15, 2022 | finance.yahoo.com

Chembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial Channel

May 17, 2022 | seekingalpha.com

Chembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facility

May 17, 2022 | finance.yahoo.com

Chembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia Facility

May 8, 2022 | seekingalpha.com

Chembio Diagnostics, Inc. (CEMI) CEO Rick Eberly on Q1 2022 Results - Earnings Call Transcript

May 5, 2022 | finance.yahoo.com

Chembio Diagnostics Reports First Quarter 2022 Financial Results

May 4, 2022 | seekingalpha.com

Chembio Diagnostics Q1 2022 Earnings Preview

April 21, 2022 | finance.yahoo.com

Chembio Diagnostics to Report First Quarter 2022 Financial Results on May 5, 2022

March 4, 2022 | benzinga.com

Why Chembio Diagnostics Shares Are Falling

March 3, 2022 | finance.yahoo.com

Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results

March 3, 2022 | seekingalpha.com

Chembio Diagnostics Q4 2021 Earnings Preview

February 17, 2022 | finance.yahoo.com

Chembio Diagnostics to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022

January 21, 2022 | nasdaq.com

Chembio Diagnostics, Inc. Common Stock (CEMI)

January 5, 2022 | seekingalpha.com

Chembio Diagnostics appoints CFO

January 5, 2022 | finance.yahoo.com

Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer

December 30, 2021 | nasdaq.com

Chembio Diagnostics Inc. Shares Close the Day 30.1% Lower - Daily Wrap

December 29, 2021 | finance.yahoo.com

Chembio Diagnostics Slides After FDA Declines to Review EUA

December 29, 2021 | markets.businessinsider.com

Pre-market Movers: PIXY, NEW, CEMI, SYTA, AUVI…

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CEMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

CEMI Company Calendar

Last Earnings: 11/04/2021
Today: 9/26/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CEMI
CUSIP: N/A
CIK: 1092662
Web: www.chembio.com
Phone: (631) 924-1135
Fax: 631-924-2065
Employees: 337
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-33,900,000.00
Net Margins: -59.52%
Pretax Margin: -59.50%
Return on Equity: -96.63%
Return on Assets: -44.99%

Debt

Debt-to-Equity Ratio: 0.82
Current Ratio: 2.91
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: $47.82 million
Price / Sales: 0.23
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 30,225,000
Free Float: 29,228,000
Market Cap: $10.87 million
Optionable: Not Optionable
Beta: 1.65

Key Executives

Mr. Richard L. Eberly (Age 61)
Pres, CEO & Director
Comp: $664.13k

Mr. Javan Esfandiari (Age 55)
Exec. VP and Chief Scientific & Technology Officer
Comp: $508.22k

Mr. Lawrence J. Steenvoorden CPA (Age 51)
Exec. VP, CFO & Sec.

Mr. Paul J. Angelico (Age 65)
EVP & COO

Ms. Stella Rivera
VP of HR

Mr. Charles Caso (Age 60)
Sr. VP of Global Commercial Operations

Dr. Konstantin Lyashchenko
Research Director of Chembio Diagnostic Systems Inc

Key Competitors

View All Competitors

CEMI Stock - Frequently Asked Questions

Should I buy or sell Chembio Diagnostics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CEMI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CEMI, but not buy additional shares or sell existing shares.
View CEMI analyst ratings or view top-rated stocks.
How have CEMI shares performed in 2022?: Chembio Diagnostics' stock was trading at $1.14 at the beginning of 2022. Since then, CEMI stock has decreased by 68.0% and is now trading at $0.3650.
View the best growth stocks for 2022 here.
When is Chembio Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our CEMI earnings forecast.
How were Chembio Diagnostics' earnings last quarter?: Chembio Diagnostics, Inc. (NASDAQ:CEMI) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative trailing twelve-month return on equity of 96.63% and a negative net margin of 59.52%. During the same quarter in the prior year, the company earned ($0.28) earnings per share.
What other stocks do shareholders of Chembio Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK).

What is Chembio Diagnostics' stock symbol?: Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
Who are Chembio Diagnostics' major shareholders?: Chembio Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Chembio Diagnostics?: Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Chembio Diagnostics' stock price today?: One share of CEMI stock can currently be purchased for approximately $0.37.
How much money does Chembio Diagnostics make?: Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $11.03 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis.
How many employees does Chembio Diagnostics have?: The company employs 337 workers across the globe.
How can I contact Chembio Diagnostics?: Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065.

This page (NASDAQ:CEMI) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial